TrialCancer medicine2019

Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Francisco-Javier Peñalver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.